Cadrenal Therapeutics Inc (NAS:CVKD) Stock News, Headlines & Updates
Cadrenal Therapeutics Inc Stock News from GuruFocus
- 1
Aug 22, 2024
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
PRNewswire • 9:00am
Aug 20, 2024
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
PRNewswire • 9:00am
Aug 14, 2024
Cadrenal Therapeutics to Present at Upcoming Investor Conferences
PRNewswire • 9:00am
Aug 07, 2024
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
PRNewswire • 4:01pm
Aug 06, 2024
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
PRNewswire • 9:00am
Jul 17, 2024
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
PRNewswire • 9:00am
Jun 11, 2024
Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
PRNewswire • 4:00pm
Jun 03, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news